Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 828 participants.

Also called NCT05650411

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 828 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05650411
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Switzerland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05650411. Randomized; single masking; primary purpose treatment. Start 2026-04-26 (actual); primary completion 2028-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)
Acronym
ULTIMATE-LM
Condition
Left Main Coronary Artery Stenosis
Intervention (Device)
LMCA PCI (percutaneous coronary intervention) with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).
Intervention (Drug)
P2Y12 inhibitor-based SAPT after short DAPT
Intervention (Drug)
Conventional DAPT
Lead sponsor
IGLESIAS Juan Fernando (class: other)
Collaborator
University of Bern (class: other)

Record details

Record id
cardio:ct-nct05650411
Content hash
9b59d563def3daf44bcb8e56fb75e4f9123c1b20cce911a0783245f88be9690a